Duration of Enoxaparin in Acute Coronary Syndrome
Enoxaparin should be administered for up to 8 days or until hospital discharge (whichever comes first) in patients with acute coronary syndrome, whether NSTEMI or STEMI. 1
Dosing Duration by Clinical Scenario
STEMI with Fibrinolytic Therapy
- Continue enoxaparin for up to 8 days following the initial bolus and subcutaneous dosing 1
- The regimen consists of an initial IV bolus followed by subcutaneous administration every 12 hours (or every 24 hours if CrCl <30 mL/min)
- This extended duration allows for continued antithrombotic protection during the vulnerable post-MI period while permitting early mobilization 2
STEMI with Primary PCI
- Enoxaparin is given as a single IV bolus (0.5-0.75 mg/kg) to support the procedure 1
- If the patient received a dose within 8 hours prior to PCI, no additional enoxaparin is needed 1
- Post-PCI continuation is typically not required as the acute intervention addresses the culprit lesion
NSTE-ACS (NSTEMI/Unstable Angina)
- Continue enoxaparin for the initial hospitalization period until percutaneous coronary intervention is performed or until hospital discharge 3
- In medically managed patients, this typically extends for several days during the acute phase
- The 2025 ACC/AHA guidelines support enoxaparin use throughout the acute management phase 1
Key Clinical Considerations
Age-Based Adjustments:
- Patients ≥75 years: No IV bolus, reduced subcutaneous dose (0.75 mg/kg every 12 hours, maximum 75 mg for first 2 doses) 1
- Patients <75 years: Standard dosing with 30 mg IV bolus, then 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses) 1
Renal Impairment:
- CrCl <30 mL/min: Reduce to 1 mg/kg subcutaneously every 24 hours regardless of age 1
Evidence Supporting This Duration
The ExTRACT-TIMI 25 trial, which established enoxaparin's superiority over unfractionated heparin in STEMI, used a treatment duration of up to 8 days 4. This landmark trial demonstrated significant reduction in 30-day mortality and recurrent MI with this regimen, and the benefit was maintained at 1-year follow-up 4. The trial specifically used enoxaparin until hospital discharge or for a maximum of 8 days, establishing this as the evidence-based duration 2, 4.
Common Pitfalls to Avoid
- Do not continue enoxaparin indefinitely beyond 8 days or hospital discharge in the acute setting
- Do not give additional enoxaparin if the last dose was within 8 hours before PCI 1
- Do not use standard dosing in elderly patients (≥75 years) or those with severe renal impairment—dose adjustments are mandatory to prevent bleeding complications 1
- Monitor for bleeding risk, particularly in patients >75 years where intracranial bleeding risk may be elevated with inappropriate dosing 2